StockData

Nektar Therapeutics vs Q32 Bio

NKTR and QTTB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NKTR and QTTB compare

Nektar Therapeutics is the larger company, worth 5.0 times as much as Q32 Bio ($1.2B against $247M).

Nektar Therapeutics scores higher on the StockData Score (9 against 8 for Q32 Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNKTRQTTB
Size and price
Market cap$1.2B$247M
Share price$36.44$8.29
Change, 1 year−32.5%275%
Change, 5 years−78.3%−91.2%
Beta (5Y)0.63−0.93
Employees6324
StockData Score
Total score9 (better)8
Valuation score1 (better)0
Growth score11
Performance score2 (better)1
Health score56 (better)
Dividend score00
Valuation
P/S22.5×–
P/B1.4× (better)2.3×
EV/EBITDA–6.5×
FCF yield−16.8%–
Growth
Revenue growth (TTM)−43.9%–
Revenue growth, 5Y average−18.4%81.9% (better)
Profitability
Gross margin100%–
Operating margin−254%–
Net margin−297%–
FCF margin−378%–
Return on equity−37.3%72.1% (better)
Return on invested capital−1186%–
Financial health
Debt / equity0.000.00
Current ratio10.4220.30 (better)
Altman Z-score−0.6713.88 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00% (better)−4.2%
Shareholder yield0.00% (better)−4.2%
Ownership
Held by institutions105%74.6%
Held by insiders0.46%28.9%
Insider net buying, 12 months−$2.2M$29.5M (better)
Short interest, % of float19.9%26.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.